Aridis Pharmaceuticals, Inc. (ARDS)
| Market Cap | 2.94M |
| Revenue (ttm) | 20.06M |
| Net Income (ttm) | -635,000 |
| Shares Out | 44.57M |
| EPS (ttm) | -0.15 |
| PE Ratio | n/a |
| Forward PE | 2.06 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,524 |
| Open | 0.0642 |
| Previous Close | 0.0642 |
| Day's Range | 0.0642 - 0.0660 |
| 52-Week Range | 0.0500 - 0.5395 |
| Beta | 1.04 |
| Analysts | Strong Buy |
| Price Target | 2.00 (+2,930.3%) |
| Earnings Date | Aug 29, 2023 |
About ARDS
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia. ... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for ARDS stock is "Strong Buy" and the 12-month stock price forecast is $2.0.
News
Aridis Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders until January 12, 2024
LOS GATOS, Calif., Dec. 15, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC QB: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies...
Aridis Pharmaceuticals Announces Third Quarter 2023 Financial Results and Business Update
Received two grant awards from the National Institute of Allergy and Infectious Diseases, a division of the National Institutes of Health
Aridis Pharmaceuticals Announces $2 Million Offering
Los Gatos, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies fo...
Aridis Receives Agreement from the European Medicines Agency (EMA) on the Clinical Study Design and a Single Confirmatory Phase 3 Study of AR-301
LOS GATOS, Calif., July 17, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced positive feedback from the European Medicines Agency (EMA) on the Company's proposed si...
Aridis' AR-301 Monoclonal Antibody is Among the First Biologics to Receive FDA's Qualified Infectious Diseases Product (QIDP) Designation
LOS GATOS, Calif., July 12, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies...
Aridis Pharmaceuticals and Rail Vision Interviews to Air on Bloomberg TV on the RedChip Money Report(R)
ORLANDO, FL / ACCESSWIRE / June 30, 2023 / RedChip Companies will air interviews with Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) and Rail Vision Ltd. (NASDAQ:RVSN) on The RedChip Money Report® on Bloo...
Aridis Pharmaceuticals Announces First Quarter 2023 Financial Results and Business Update
LOS GATOS, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies...
Aridis Pharmaceuticals Receives Nasdaq Notice on Late Filing of its Form 10-Q
LOS GATOS, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) (“Aridis” or the “Company”), a biopharmaceutical company, announced today that it received a notice (the...
Aridis Pharmaceuticals Receives Nasdaq Notice on Late Filing of its Form 10-K
LOS GATOS, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) (“Aridis” or the “Company”), a biopharmaceutical company, announced today that it received a notice (t...
Aridis Provides Corporate Update
LOS GATOS, Calif., March 31, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) (“Aridis” or the “Company”), a biopharmaceutical company, today announced a corporate update on recent...
Aridis Pharmaceuticals Announces $2.28 Million Registered Direct Offering of Common Stock
Los Gatos, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company, today announced that it has entered into a definitive agreement for the ...
Interviews with Rail Vision, Aridis Pharmaceuticals, and Digital Ally to Air on Bloomberg U.S. on the RedChip Money Report(R)
ORLANDO, FL / ACCESSWIRE / February 17, 2023 / RedChip Companies will air new interviews with Rail Vision Ltd. (Nasdaq:RVSN), Aridis Pharmaceuticals, Inc. (Nasdaq:ARDS), and Digital Ally, Inc. (NASDAQ...
Aridis Reports Top-Line Results of the Phase 3 Double-Blinded, Superiority Trial of AR-301 For the Treatment of Staphylococcus aureus Ventilator Associated Pneumonia (VAP)
LOS GATOS, Calif, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced top-line results from the AR-301-002 Phase 3 study, which evaluated the superiority of a...
New Approaches to Treating Infections in Cystic Fibrosis Patients - AR 501 Phase 2 Trial Update
AR-501 is an inhaled formulation of gallium citrate with broad-spectrum anti-infective activity being developed to treat chronic lung infections in CF patients
Aridis Pharmaceuticals to Discuss Topline Data from Phase 3 Study of AR-301 During Corporate Update Call on January 25
Los Gatos, Calif., Dec. 28, 2022 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS) , a biopharmaceutical company focused on the discovery and development of novel anti-infective therapie...
(Updated) Aridis Pharmaceuticals Receives Equity Investment from the Cystic Fibrosis Foundation
Los Gatos, Calif., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS) , a biopharmaceutical company today announced the Cystic Fibrosis Foundation invested $4.85 million in ...
Aridis Pharmaceuticals Receives Equity Investment from the Cystic Fibrosis Foundation
Los Gatos, Calif., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS) , a biopharmaceutical company today announced the Cystic Fibrosis Foundation invested $4.85 million in ...
Aridis Signs Exclusive Terms to Secure Worldwide Commercial Licenses for Pan-Ebola and Pan-Marburg Monoclonal Antibody Programs from Mapp Biopharmaceutical
Los Gatos, Calif., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS) , a biopharmaceutical company focused on the discovery and development of novel anti-infective therapie...
Aridis to Participate in Key Opinion Leader Discussion on Immunotherapy for Infectious Diseases
Los Gatos, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS) , a biopharmaceutical company focused on the discovery and development of novel anti-infective therapie...
Aridis Pharmaceuticals Announces Third Quarter 2022 Financial Results and Business Update
Top-line data from the Phase 3 clinical trial evaluating AR-301 for the treatment of VAP expected in December of this year
Aridis Announces the Closing of Patient Enrollment in the AR-301 Global Phase 3 Superiority Study
On track to complete data compilation and analyses, with top-line data expected to be announced in December '22 LOS GATOS, Calif. , Oct. 4, 2022 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (NASDAQ: A...
Aridis Pharmaceuticals Announces Withdrawal of Public Offering of Common Stock
LOS GATOS, Calif. , Sept. 27, 2022 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies t...
Aridis Pharmaceuticals Announces Proposed Public Offering of Common Stock
LOS GATOS, Calif. , Sept. 26, 2022 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies t...
Aridis Pharmaceuticals Announces Second Quarter 2022 Financial Results and Business Update
Multiple clinical data readouts expected in second half of 2022 LOS GATOS, Calif. , Aug. 16, 2022 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on th...
Aridis' Pan-Coronavirus, Inhaled Monoclonal Antibody Cocktail AR-701 Is Protective in Non-Human Primates
AR-701 is effective in vitro against SARS-CoV-2 Omicron subvariants, including BA.4 and BA.5 LOS GATOS, Calif. , Aug. 10, 2022 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmac...